NASDAQ:ALNYAlnylam Pharmaceuticals Stock Price, Forecast & News

Alnylam Pharmaceuticals' stock was trading at $101.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ALNY shares have increased by 52.5% and is now trading at $155.38. View which stocks have been most impacted by Coronavirus.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) posted its quarterly earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($1.62) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($1.89) by $0.27. The biopharmaceutical company had revenue of $71.94 million for the quarter, compared to analyst estimates of $90.45 million. Alnylam Pharmaceuticals had a negative net margin of 310.01% and a negative return on equity of 57.63%. The firm's revenue for the quarter was up 173.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.42) EPS. View Alnylam Pharmaceuticals' earnings history.

18 brokerages have issued 1-year price targets for Alnylam Pharmaceuticals' shares. Their forecasts range from $74.00 to $202.00. On average, they expect Alnylam Pharmaceuticals' share price to reach $151.28 in the next twelve months. This suggests that the stock has a possible downside of 2.6%. View analysts' price targets for Alnylam Pharmaceuticals.

Media coverage about ALNY stock has been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Alnylam Pharmaceuticals earned a coverage optimism score of -1.5 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Alnylam Pharmaceuticals.

Some companies that are related to Alnylam Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), NVIDIA (NVDA), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), Opko Health (OPK), AbbVie (ABBV) and Vertex Pharmaceuticals (VRTX).

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

Alnylam Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Envestnet Asset Management Inc. (0.03%), State of Alaska Department of Revenue (0.02%), DNB Asset Management AS (0.01%), IFM Investors Pty Ltd (0.01%), IBM Retirement Fund (0.00%) and Sanders Morris Harris LLC (0.00%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Marsha Fanucci, Philip A Sharp, Phillip A Sharp, Steven M Paul and Yvonne Greenstreet. View institutional ownership trends for Alnylam Pharmaceuticals.

ALNY stock was sold by a variety of institutional investors in the last quarter, including IFM Investors Pty Ltd. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Marsha Fanucci, Phillip A Sharp, Steven M Paul, and Yvonne Greenstreet. View insider buying and selling activity for Alnylam Pharmaceuticals.

ALNY stock was acquired by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., State of Alaska Department of Revenue, DNB Asset Management AS, Sanders Morris Harris LLC, and IBM Retirement Fund. View insider buying and selling activity for Alnylam Pharmaceuticals.

Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALNY stock can currently be purchased for approximately $155.38.

Alnylam Pharmaceuticals has a market capitalization of $17.92 billion and generates $219.75 million in revenue each year. The biopharmaceutical company earns $-886,120,000.00 in net income (profit) each year or ($8.11) on an earnings per share basis. Alnylam Pharmaceuticals employs 1,323 workers across the globe.

The official website for Alnylam Pharmaceuticals is www.alnylam.com.

Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-551-8200 or via email at [email protected]